D A DeNardo
Overview
Explore the profile of D A DeNardo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
97
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
ODonnell R, Leigh B, Christensen S, Goldstein D, Kukis D, Shen S, et al.
Cancer Biother Radiopharm
. 2000 Jun;
14(3):167-76.
PMID: 10850301
Standard therapy for AIDS associated NHL (AANHL) is toxic and often ineffective. Radioimmunotherapy (RIT) is an appealing alternative to chemotherapy because of the radiosensitivity of NHL and the ability of...
2.
Denardo G, Denardo S, Shen S, DeNardo D, Mirick G, Macey D, et al.
J Nucl Med
. 1999 Aug;
40(8):1317-26.
PMID: 10450684
Unlabelled: Lym-1, a monoclonal antibody that preferentially targets malignant lymphocytes, has induced therapeutic responses in patients with non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) when labeled with 131I. Responders...
3.
Denardo G, Kukis D, Shen S, DeNardo D, Meares C, Denardo S
Clin Cancer Res
. 1999 Apr;
5(3):533-41.
PMID: 10100704
Antilymphoma mouse monoclonal antibody (MoAb) Lym-1, labeled with 67Cu or 131I, has demonstrated promising results in radioimmunotherapy (RIT) for lymphoma. Although 131I has played a central role in RIT thus...
4.
Denardo S, Denardo G, Kukis D, Shen S, Kroger L, DeNardo D, et al.
J Nucl Med
. 1999 Feb;
40(2):302-10.
PMID: 10025839
Unlabelled: Lym-1, a monoclonal antibody that preferentially targets malignant lymphocytes, has induced therapeutic responses and prolonged survival in patients with non-Hodgkin's lymphoma when labeled with 1311. Radiometal-labeled antibodies provide higher...
5.
Denardo G, Denardo S, Kukis D, ODonnell R, Shen S, Goldstein D, et al.
Anticancer Res
. 1998 Aug;
18(4B):2779-88.
PMID: 9713461
Purpose: Lym-1, a monoclonal antibody (MoAb) that preferentially targets malignant lymphocytes, has induced therapeutic responses in patients with non-Hodgkin's lymphoma (NHL) when labeled with iodine-131 (131I). Radiometal labeled antibodies provide...
6.
Denardo G, Shen S, Denardo S, Liao S, Lamborn K, DeNardo D, et al.
Eur J Nucl Med
. 1998 Jun;
25(5):497-502.
PMID: 9575245
Accurate and reproducible quantification of tumor radioactivity by imaging requires definition of a region of interest (ROI) for the tumor. The use of a threshold for creating the tumor ROI...
7.
DeNardo D, Denardo G, ODonnell R, Lim S, Shen S, Yuan A, et al.
Cancer
. 1997 Dec;
80(12 Suppl):2558-66.
PMID: 9406710
Background: The severity of myelotoxicity after radioimmunotherapy has been predicted from body and blood radiation doses to marrow. However, marrow radiation can be increased substantially if the marrow or skeleton...
8.
Shen S, Denardo G, ODonnell R, Yuan A, DeNardo D, Denardo S
Cancer
. 1997 Dec;
80(12 Suppl):2553-7.
PMID: 9406709
Background: Patients with B-cell non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) frequently have splenomegaly, which has been reported to cause poor tumor targeting of radiolabeled antibodies. Consequently, patients with...
9.
Lim S, Denardo G, DeNardo D, ODonnell R, Yuan A, Denardo S
J Nucl Med
. 1997 Nov;
38(11):1749-53.
PMID: 9374345
Unlabelled: Marrow radiation with resultant myelosuppression is usually dose-limiting in radioimmunotherapy (RIT). This study evaluated the relationship between a semiquantitative score of radiolabeled antibody marrow uptake obtained by imaging and...
10.
Lim S, Denardo G, DeNardo D, Shen S, Yuan A, ODonnell R, et al.
J Nucl Med
. 1997 Sep;
38(9):1374-8.
PMID: 9293790
Unlabelled: Bone marrow is generally the dose-limiting organ in radioimmunotherapy (RIT). Although radiation doses to marrow estimated from tracer doses have been shown to be comparable to those from therapy...